Dr David Collier
Clinical Director
Centre: Clinical Research Centre, Clinical Pharmacology and Precision Medicine
Email: d.j.collier@qmul.ac.uk Telephone: +44(0) 20 7882 5666
Profile
ORCID iD: 0000-0003-0866-4058
David is interested in recruitment and patient engagement and ran the successful “Future of Clinical Trials in the UK?” meeting in 2008 and “Everything you wanted to know about clinical trials but were too afraid to ask” for PCRN and Barts NIHR Cardiovascular BRU in 2011. Clinical Trials- Sharing Our Stories in July 2013 included trials patients, U3A members and co-ordinators, health psychology undergraduates from Florida State University, and sixth form students from a wide area under the banner of Trials Connect.
He is co-holder of an MRC programme grant examining recruitment methods for clinical trials (START) with the NIHR PCRN Research Recruitment Methods Group (ResRecMG), and is part of the NIHR Cardiovascular Biomedical Research Unit at Barts and The London.
David founded the East London spoke for the Primary Care Research Network for Greater London (PCRN-GL).
Renal Denervation with Dr Mel Lobo was a UK first in 2010 which yielded both a front page banner headline in the Daily Telegraph and National TV news on News at 6 O’clock and News at Ten for Dr Lobo and Fred Quatromini.
The first case in the world of renal sympathetic nerve denervation to bilateral renal arteries was done here as part of this study cohort.The subsequent publication in the Lancet for Dr Lobo and Professor Caulfield for Symplicity 2
Patients presented with David to the audience at both of the National Symposia on Renal Denervation – the first in October 2011 (Fred Quatromini), the second in 2012 (Sheila Milson and Anthony Henry), both at the Royal College of Physicians.
After the First UK Symposium on Renal Denervation in 2011, there was an initial meeting of the Joint British Societies to develop guidelines for renal denervation. Subsequent meetings developed a consensus statement and two of our patients, John Bold and Anthony Henry, contributed to meeting discussions and provided comments on the statement, especially with reference to the suggested patient information sheet for the procedure.
Research
Dr David Collier is Research Fellow and Joint Clinical Director of the William Harvey Research Institute Clinical Research Centre. Now based at the Heart Centre at Barts, David ran the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) team for Professor Caulfield at Barts/London, which broke the national record for recruitment into such a trial (recruiting 1157 patients). As top academic recruiters for several studies across over a decade, this team has contributed to high-impact work such as ILLUMINATE, with 148 patients (NEJM 2007 Barter, Caulfield et al ).
ASCOT became a landmark trial and precipitated the development of joint NICE/BHS guidelines for hypertension after the publication of the Blood Pressure Lowering Arm (BPLA) in the Lancet in 2005 (prior to this time there had been separate NICE and BHS (British Hypertension Society) Guidelines on the treatment of hypertension in the UK- which had been unhelpful.
ASCOT impacted the lipid guidance from NICE on statin use in primary prevention of ischaemic heart disease and stroke- bringing routine use of statins for people at elevated absolute risk, regardless of starting levels of cholesterol.
The experience of ASCOT and local GP’s reactions to it such as “what did you do with Mrs Smith that I hadn’t done- you got her pressure down?” led David to obtain initial funds as unconditional educational grants from rival pharma companies Pfizer and Merck and to design HiLo, a health services intervention trial. Having designed the trial interventions with Dr Catherine Will (then Cambridge, now University of Sussex) and piloted them at Chrisp Street in Limehouse, the design was developed with Dr John Robson and Prof Sandra Eldridge.
Publications
-
Simader FA, Rajkumar CA, Foley MJ et al. (2024). Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease. nameOfConference
-
Bakris GL, Saxena M, Gupta A et al. (2024). RNA Interference With Zilebesiran for Mild to Moderate Hypertension. nameOfConference
-
Collier DJ, Taylor M, Godec T et al. (2024). Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial). nameOfConference
-
Gupta A, Whiteley WN, Godec T et al. (2024). Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial. nameOfConference
-
Rajkumar CA, Foley MJ, Ahmed-Jushuf F et al. (2023). A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. nameOfConference
-
Madurasinghe VW, Knapp P, Eldridge S et al. (publicationYear). Can we achieve better trial recruitment by presenting patient information through multimedia? Meta-analysis of ‘studies within a trial’ (SWATs). nameOfConference
QMRO: qmroHref -
Pairo-Castineira E, Rawlik K, Bretherick AD et al. (2023). Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 (Nature, (2023), 617, 7962, (764-768), 10.1038/s41586-023-06034-3). nameOfConference
-
Clohisey S, Millar J, Shankar-Hari M et al. (2023). GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. nameOfConference
-
Schlaich MP, Bellet M, Weber MA et al. (2022). Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. nameOfConference
-
Nowbar AN, Howard JP, Shun-Shin MJ et al. (2022). Daily angina documentation versus subsequent recall: development of a symptom smartphone app. nameOfConference
QMRO: qmroHref